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Anthrax toxin receptors 1 and 2 (ANTXR1 and ANTXR2) have a related integrin-like inserted (I) domain which interacts
with a metal cation that is coordinated by residue D683 of the protective antigen (PA) subunit of anthrax toxin. The
receptor-bound metal ion and PA residue D683 are critical for ANTXR1-PA binding. Since PA can bind to ANTXR2 with
reduced affinity in the absence of metal ions, we reasoned that D683 mutant forms of PA might specifically interact
with ANTXR2. We show here that this is the case. The differential ability of ANTXR1 and ANTXR2 to bind D683 mutant
PA proteins was mapped to nonconserved receptor residues at the binding interface with PA domain 2. Moreover, a
D683K mutant form of PA that bound specifically to human and rat ANTXR2 mediated killing of rats by anthrax lethal
toxin, providing strong evidence for the physiological importance of ANTXR2 in anthrax disease pathogenesis.
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Introduction
The spore-forming bacterium Bacillus anthracis causes
anthrax and is classiﬁed as one of seven Centers for Disease
Control and Prevention category A agents that are consid-
ered major threats as bioweapons [1]. B. anthracis secretes a
toxin which contributes to bacterial virulence and causes
many of the disease symptoms. Anthrax toxin is an AB-type
toxin, with a single receptor-binding B-moiety, protective
antigen (PA), and two catalytic A-moieties, lethal factor (LF)
and edema factor (EF). LF is a zinc-dependent metallopro-
tease that cleaves members of the mitogen-activated protein
kinase kinase family (all MKKs except MEK5) [2–4], whereas
EF is a calmodulin and calcium–dependent adenylate cyclase
[5,6]. LF and PA combine to form lethal toxin, and EF and PA
combine to form edema toxin. These toxins are responsible
for disabling host innate and adaptive immune responses,
causing vascular leakage, and leading to the death of animals
and cultured cells [7–16].
Following binding of PA to cell surface receptors and
internalization of toxin complexes, EF and LF are trans-
located into the cytoplasm through a heptamerized PA pore
that forms at endosomal low pH [17–20]. There are two
known cell surface receptors for PA, ANTXR1 (anthrax toxin
receptor/tumor endothelial marker 8; ATR/TEM8) and
ANTXR2 (capillary morphogenesis gene 2; CMG2) [21,22].
These receptors are expressed in various human tissues [22–
24], but there is evidence that ANTXR1 may be preferentially
expressed in cancer cells and tumor endothelium [25–29].
The relative importance of either receptor for anthrax
disease pathogenesis has not been established.
PA interacts with both receptors through a common von
Willebrand factor A/integrin-like inserted (I) domain that
contains a metal ion adhesion site (MIDAS) with ﬁve metal
ion coordinating residues [30]. Similar to binding of ligands
to a-integrins, binding of PA to its receptors involves direct
coordination of a divalent cation in the MIDAS by a
carboxylate-containing side chain from PA (residue D683)
[31–34] (Figure 1). Previous studies have shown that PA
residue D683 is critical for intoxication of cells via ANTXR1
[34].
The ANTXR2 I domain binds to PA domains 2 and 4, and
the surface area of the protein interface is much larger
(approximately 2,000 A ˚ 2)t h a nt h a to fa-integrin–ligand
interactions (approximately 1,300 A ˚ 2) [31,32]. The large
contact surface correlates with a very tight ANTXR2 I
domain–PA binding afﬁnity (KD ¼ 170 or 780 pM in Mg
2þ
or Ca
2þ, respectively) [35], compared with the afﬁnity of a-
integrin–ligand interactions that are usually in the micro-
molar to millimolar range [36]. ANTXR2 I domain contact
with PA domain 2, the domain that forms pores and
translocates EF/LF, has been proposed to act as a molecular
clamp that prevents pore formation until the complex is
trafﬁcked to a low pH endosomal compartment [20,31,32,37]
(Figure 1).
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ANTXR1 and ANTXR2, there are striking differences in the
PA binding activities of the two receptors. When the PA
heptamer is bound to ANTXR2, a pH value of approximately
5.0 is required to allow efﬁcient pore formation, whereas
approximately pH 6 is required for PA pore formation when
the toxin is bound to ANTXR1 [20,37]. Also, the metal-
dependent PA binding afﬁnity of the ANTXR1 I domain is
weaker than that of ANTXR2 by approximately 1,000-fold (KD
¼130 nM or 1.1 lMi nM g
2þor Ca
2þ, respectively) [38]. Indeed,
the ANTXR1 I domain–PA binding afﬁnity in the presence of
metal ions is similar to the ANTXR2 I domain–PA binding
afﬁnity in the absence of metal ions (KD ¼ 960 nM in EDTA/
EGTA) [35].
Because PA-ANTXR2 binding appeared to be less depend-
ent on interactions mediated by the metal ion, we reasoned
that the PA–ANTXR2 interaction should be less sensitive to
mutations of PA residue D683. Here we show that this is the
case and that PA proteins with D683 mutations bind
speciﬁcally to human and rodent ANTXR2 and mediate
intoxication via these receptors. We also show that a single
region of nonconserved receptor residues that bind PA
domain 2 is responsible for the differential abilities of
ANTXR1 and ANTXR2 to bind D683 mutant forms of PA.
Moreover, we demonstrate that a D683K mutant form of PA
mediates lethal toxin killing of rats, implicating ANTXR2 as a
physiologically important anthrax toxin receptor.
Results
PA Residue D683 Is Not Essential for Binding or
Intoxication via ANTXR2
Previously, PA residue D683, which contacts the receptor-
bound metal ion (Figure 1), was shown to be critically
important for the interaction of PA with ANTXR1: mutation
of this residue to Asn completely abrogated receptor binding
[34]. To test the dependence of ANTXR2-PA binding on PA
D683, this residue was replaced with either an asparagine or a
lysine. The resultant PA
D683N and PA
D683K proteins were
tested for their abilities to bind to a soluble human ANTXR2
protein (sANTXR2) and a full-length human ANTXR2–
enhanced green ﬂuorescent protein (EGFP) fusion protein
expressed on PA receptor-deﬁcient Chinese hamster ovary
(CHO)-R1.1 cells. Additionally, cells expressing ANTXR2-
EGFP were tested for their ability to be intoxicated with
PA
D683N or PA
D683K and LFN-DTA, a recombinant protein
composed of the N-terminal PA-binding portion of LF fused
to the catalytic A chain of diphtheria toxin, which kills CHO
cells. For control purposes, these experiments were also
Figure 1. ANTXR2 Binding to PA Domains 2 and 4
Ribbon model of the PA-ANTXR2 complex generated with UCSF Chimera
[32]. PA domains 2 (D2) and 4 (D4) are shown in dark cyan and
aquamarine, respectively, and the remainder of PA is depicted in gray.
The ANTXR2 I domain is depicted in pink with its chelated metal ion in
green. The ANTXR2 G153 and L154 residues (orange), which contact PA
domain 2, and PA D683 residue (blue), which binds the receptor cation,
are shown in stick representation. The ANTXR2 152–157 region is shown
in yellow.
DOI: 10.1371/journal.ppat.0020111.g001
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Synopsis
The bacterium that causes anthrax produces a toxin which is largely
responsible for the symptoms and death associated with this
disease. The toxin acts by first docking onto specific proteins, called
receptors, located on the host cell surface, and it is then taken up
into cells where it can act on its cellular substrates. There are two
known receptors for the toxin, anthrax toxin receptors 1 and 2
(ANTXR1 and ANTXR2). However, the physiological importance of
each receptor in host organisms is not yet understood. To address
this issue directly, the authors designed a form of the toxin which
binds specifically to ANTXR2 but not to ANTXR1. They show that this
ANTXR2-specific form of the toxin is capable of killing rats following
intravenous injection. These studies provide direct evidence for the
physiological importance of ANTXR2 in anthrax toxin action in a
model host organism.performed with CHO-R1.1 cells engineered to express a
human ANTXR1-EGFP fusion protein.
Surface plasmon resonance (SPR) analysis, performed as
described previously [35], revealed that PA
D683N binds tightly
to the sANTXR2 I domain, KD¼28 (61.7) and 17 (60.68) nM
in the presence of Ca
2þ and Mg
2þ, respectively. This binding
was still metal ion dependent because the KD value was 240
(627) nM in the presence of EDTA, a metal chelator. PA
D683K
bound the soluble receptor with similar properties, KD ¼ 26
(60.81) and 33 (63.1) nM, in Ca
2þ and Mg
2þ, respectively, and
was 94 (68.8) nM when EDTA was added.
Flow cytometric analysis performed with one of the altered
proteins, PA
D683K, conﬁrmed that it bound to cells expressing
ANTXR2-EGFP but not ANTXR1-EGFP (Figure 2A, 2B, and
2C). Consistently, both PA
D683N and PA
D683K supported the
intoxication of cells expressing human ANTXR2-EGFP
(Figure 2D) but not ANTXR1-EGFP (Figure 2E). Indeed, cells
expressing ANTXR2-EGFP were just as susceptible to
PA
D683K-dependent killing as they were to wild-type PA-
dependent killing (Figure 2D). We conclude that PA residue
D683 is not critical for toxin action mediated by ANTXR2 in
the range of toxin concentrations tested.
ANTXR2 Residues That Interact with PA Domain 2 Specify
the D683 Mutant PA Interaction
Based on the co-crystal structures of ANTXR2 bound to PA
(Figure 1), there are eight contact residues that would be
different at the toxin-binding interface in ANTXR1: A56L,
N57H, Q88R, S113L, V115G, D152H, G153E, and L154D
[31,32] (Figure S1). We reasoned that the differential abilities
of the receptors to bind mutant PA proteins would be due to
one or more of these variable amino acids. To test this idea,
each of these amino acid substitutions was introduced
independently into ANTXR2-EGFP and the altered receptors
were expressed in transiently transfected CHO-R1.1 cells. Cell
surface expression of the mutant receptors was conﬁrmed by
ﬂow cytometry with a polyclonal chicken anti-ANTXR2
serum and AlexaFluor-633–conjugated secondary antibody
(Figure 3A). These cells were also subjected to intoxication
with PA
D683N and LFN-DTA. Cell viability was measured in a
ﬂow cytometry–based assay where the percentage of live,
EGFP-positive cells remaining after toxin challenge was
compared with cells incubated with LFN-DTA alone (no
toxin killing). Cells expressing cytoplasmic EGFP or
ANTXR1-EGFP were included as negative controls.
The largest defects in PA
D683N-mediated intoxication were
seen with cells expressing G153E or L154D mutant ANTXR2
receptors (Figure 3A). Residues G153 and L154 are located in
a surface region of ANTXR2 that contacts PA domain 2
(Figure 1). To further investigate the role of this region in the
D683 mutant PA interaction, we made reciprocal exchanges
of the residues located between positions 152 and 157
(DGLVPS) in the b4-a4 loop region of the ANTXR2 I domain
and the corresponding residues of ANTXR1 (154 to 159;
HEDLFF) in the context of ANTXR1-EGFP and ANTXR2-
EGFP proteins, respectively. These studies revealed that
replacement of both G153 and L154 residues in ANTXR2
with the residues from ANTXR1 was sufﬁcient to make cells
completely resistant to PA
D683N intoxication (Figure 3B).
Additionally, replacement of ANTXR1 residues 154 to 159
with the corresponding ANTXR2 residues gave rise to a
recombinant receptor that could support PA
D683N-mediated
intoxication (Figure 3B).
PA
D683K Supports LF-Mediated Intoxication in Rats
To address the possible role of ANTXR2 in lethal toxin
killing of Fischer 344 rats, we ﬁrst conﬁrmed that D683
mutant forms of PA can interact with rat ANTXR2
(rANTXR2) but not rat ANTXR1. To this end, we attempted
to isolate a full-length rat ANTXR1 cDNA clone but were not
Figure 2. PA
D683N and PA
D683K Bind and Support Intoxication via ANTXR2
CHO-R1.1cellsstablyexpressinghumanANTXR2-EGFP(A),humanANTXR1-EGFP(B),andcontrolCHO-R1.1cellsexpressingnoreceptors(C)wereanalyzed
byflowcytometryafterincubationwith100nMpurifiedPAorPA
D683Kproteins,followedbyananti-PAserum,andanAPC-conjugatedsecondaryantibody.
TriplicatesamplesofCHO-R1.1cellsstablyexpressinghumanANTXR2-EGFP(D)orhumanANTXR1-EGFP(E)wereincubatedwith10
 10MLF N-DTA,andwith
increasing amounts of either purified PA, PA
D683N,o rP A
D683K proteins. Cell viability was measured by CellTiter-Glo reagent and is represented as the
percentage of signal seen with cells incubated with LFN-DTA alone (100% viable).
DOI: 10.1371/journal.ppat.0020111.g002
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ANTXR2-Dependent Anthrax Intoxicationsuccessful. However, the rat ANTXR1 I domain differs from
that of its human counterpart by only two amino acids
(residues K72 and R136 of the human protein are, in the rat
protein, arginine and serine, respectively). Therefore, we
constructed a rat version of the ANTXR1-EGFP protein
(designated as ANTXR1
R72,S136-EGFP by replacing these two
human-speciﬁc residues with those of rat ANTXR1. Also,
cDNAs encoding the rANTXR2 open reading frame were
isolated from rat liver and brain tissue RNAs; both cDNAs
had an identical DNA sequence. Comparison with the human
ANTXR2 (hANTXR2) revealed that the I domains of these
proteins differ by ten amino acid acids, two of which are PA-
contact residues: Arg111 and Ser113 in hANTXR2 are alanine
and glutamine in rANTXR2, respectively (Figure S1). CHO-
R1.1 cells engineered to express rANTXR2-EGFP were
susceptible to PA
D683K-dependent killing, albeit slightly less
efﬁciently than the killing observed with wild-type PA (Figure
4A and 4B). By contrast, cells engineered to express either
hANTXR1-EGFP or ANTXR1
R72,S136-EGFP were resistant to
PA
D683K-dependent killing. Taken together, these observa-
tions conﬁrm that PA
D683K interacts speciﬁcally with
ANTXR2, both in humans and in rats.
In an initial experiment, it was found that PA
D683K could
support lethal toxin-killing of male Fischer 344 rats, albeit
several-fold less efﬁciently than that seen with wild-type PA:
the mean time to death (TTD) (6SD) seen with three animals
injected intravenously with 8 lg of LF and 10 lg of wild-type
PA was 93.3 (610.2) minutes, similar to that seen with two
animals injected with four times as much PA
D683K and the
same amount of LF, i.e., TTD ¼ 98.5 (610.6) minutes. This
several-fold decrease in the efﬁcacy of PA
D683K was also
apparent from comparing the mean TTD of two animals
Figure 3. ANTXR2 Contact with PA Domain 2 Confers Sensitivity to PA
D683N-Mediated Intoxication
(A) Triplicate samples of CHO-R1.1 cells transiently expressing ANTXR2, or ANTXR2 proteins with alterations in PA contacts to nonconserved ANTXR1
residues were incubated with 10
 10 ML F N-DTA and 10
 7 MP A
D683N,o rL F N-DTA only, and analyzed by flow cytometry. The average percentage of live
EGFP-positive cells in the samples with both parts toxin is divided by that in the LFN-DTA only samples to determine percent cell viability (black bars).
Individual samples of the same cells were also incubated with an anti-ANTXR2 antibody, followed by an AlexaFluor-633–conjugated secondary antibody
and analyzed by FACS to determine the receptor cell surface expression level. The geometric mean of AlexaFluor-633 fluorescence after staining cells
with antibodies (gray bars) is depicted next to the cell viability data for comparison purposes.
(B) Receptor sequencesresponsiblefor contacting PA domain 2 were exchanged betweenANTXR1 andANTXR2 proteins in an analysis similar to (A). Cells
expressing ANTXR1
154–159 bound anti-ANTXR2 antibodies, suggesting that an epitope for the polyclonal antibody mapped to this site. Saturable binding
studies performed with transfected cells and with increasing amounts of an AlexaFluor-633–labeled monomeric PA protein confirmed that the mutant
154–159 ANTXR1 protein is expressed on the cell surface at levels similar to wild-type ANTXR1 and ANTXR2 (unpublished data).
DOI: 10.1371/journal.ppat.0020111.g003
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ANTXR2-Dependent Anthrax Intoxicationinjected with 200 lg of this mutant protein and LF (TTD ¼
68.5 [65.0] minutes compared to those of three animals in
each group that received LF with either 20, 30, or 40 lgo f
wild-type PA [mean TTD¼60.3 6 2.9; 57.0 6 2.0; and 54.7 6
1.5 minutes, respectively]).
To investigate the relative efﬁcacy of PA
D683K in more
detail, a subsequent experiment was performed with rats
injected with the same amount of LF and with either a ﬁxed
amount of PA
D683K (100 lg) or varying amounts of wild-type
PA (ranging from 10 to 40 lg). Rats injected with LF and 100
lgo fP A
D683K died on average approximately 67 min
following toxin administration (Figure 4C). By comparison,
rats injected with LF and either 20 lgo fP Ao r1 0lgo fP A
died an average of approximately 64 and 89 min after toxin
injection, respectively (Figure 4C). The difference in TTD
between the rats treated with 100 lgo fP A
D683K was
statistically signiﬁcant when compared with those injected
with 10 lgo fP A( P¼0.0001) but not from those treated with
20 lgo fP A( P ¼ 0.104) (Figure 4C). Based on these dosage
effects, we conclude that PA
D683K can mediate anthrax lethal
toxin killing of rats, albeit with an approximately 5-fold
reduced efﬁciency compared with wild-type PA.
Discussion
This report demonstrates that D683 mutant forms of PA
bind selectively to ANTXR2 and that this selectivity is
dependent on amino acid residues of ANTXR2 that contact
domain 2 of PA. Moreover, we have shown that a D683K
mutant form of PA is capable of mediating lethal toxin killing
of rats, implicating an important physiological role for
ANTXR2 in this process.
We have demonstrated that the ability of ANTXR2 to bind
PA proteins with mutations at the D683 site maps to the
receptor surface region containing residues G153 and L154
that engage PA domain 2. Replacing the ANTXR2 G153,
which allows a polypeptide backbone turn, and L154, which
participates in hydrophobic interactions with PA, with the
negatively charged Glu and Asp residues from ANTXR1
resulted in resistance to cellular intoxication with PA
D683N.
By contrast, exchange of the HEDLFF
154–159 sequence from
ANTXR1 for the corresponding DGLVPS
152–157 sequence
from ANTXR2 conferred upon ANTXR1 the ability to
support PA
D683N-mediated intoxication.
Prior to this report it was unclear if ANTXR2 was
important for lethal toxin killing in vivo. Our results showing
that PA
D683K supports lethal toxin-mediated killing of rats
provides direct evidence for the physiological importance of
this receptor in this rodent model system. There are several
potential explanations for the reduced efﬁcacy of PA
D683K in
vivo, compared to wild-type PA. First, this result could reﬂect
the slightly reduced levels of PA
D683K intoxication observed
in cultured cells expressing rANTXR2 relative to those
expressing hANTXR2. This difference may be due to the
combined effects of residue differences at positions 111 and
113 of these proteins. The hANTXR2 R111 residue interacts
Figure 4. PA
D683K Supports Lethal Toxin-Mediated Killing of Rats via
rANTXR2
(A) Triplicate samples of CHO-R1.1 cells transiently expressing the
different receptor-EGFP proteins were incubated with 10
 10 ML F N-DTA
and with either 10
 8 M wild-type PA or 10
 7 MP A
D683K or without PA.
These amounts of wild-type and mutant PA proteins were used because
they gave rise to maximal levels of killing when incubated with cells
expressing human ANTXR2 (Figure 1D). Cell viability was measured by
counting the percentage of live EGFP-positive cells in the sample by flow
cytometry and is expressed as described in the Figure 3A legend.
(B) Triplicate samples of CHO-R1.1 cells transiently expressing
ANTXR1
R72,S136-EGFP were incubated with toxin and analyzed as in (A)
except that increasing amounts of either the wild-type or mutant PA
protein were used.
(C)Groupsoffiveratseachwereinjectedbyjugularveincannulawith8lg
ofLFandeither100lgofPA
D683Kor10to40lgofPAandtimeuntildeath
postinjection was recorded. One rat in the 40 lg PA group died
immediately after injection from pulmonary embolism and was excluded
from analysis. Each data point represents a single animal, and the vertical
line represents the mean for each group. P-values were determined by
Student’s unpaired t-test. Control rats injected with PBS all survived
(unpublished data).
DOI: 10.1371/journal.ppat.0020111.g004
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ANTXR2-Dependent Anthrax Intoxicationwith a negatively charged environment in PA domain 4, and
the S113 residue makes H-bond contacts with PA domain 4 in
the crystal structure (unpublished data) [31,32]. The
rANTXR2 Ala and Gln residues at these respective locations
may not be able to participate in these interactions. A second
possibility is that cell type–speciﬁc differences downstream of
initial PA binding might dictate different activities of PA
proteins with altered residues at the D683 site. Indeed, we
observed a 10-fold difference in intoxication activities of the
PA
D683N and PA
D683K proteins despite similar ANTXR2
binding afﬁnities (Figure 2D and 2E). Third, the reduced
activity of the PA
D683K protein in vivo might be indicative of a
role for ANTXR1 in intoxication of rats by wild-type lethal
toxin.
The PA
D683K protein is the ﬁrst engineered toxin that can
discriminate between the two anthrax toxin receptors, bind-
ing speciﬁcally to ANTXR2. This ANTXR2-speciﬁc form of PA
can now be used to study the role of ANTXR2 in mediating the
effects of lethal toxin in other cell types, and it can also be
engineered into the bacterium to probe the importance of
this receptor for various aspects of anthrax disease patho-
genesis following infection with B. anthracis spores.
Materials and Methods
DNA constructs and cell lines. The ANTXR2-EGFP, ANTXR1-
EGFP, and sANTXR2-mycHis fusion constructs have already been
described (CMG2
489-EGFP, ATR/TEM8 sv2-EGFP, and sCMG2-my-
cHis, respectively) [22,38]. QuikChange mutagenesis (Stratagene, La
Jolla, California, United States) was performed with the oligonucleo-
tide primers in Table S1 to generate various mutant versions of the
ANTXR2-EGFP and ANTXR1-EGFP fusion constructs in the retro-
viral vector pLEGFP.N1 [22]. The QuikChange mutagenesis method
was also used with the primers listed in Table S1 to generate the
PA
D683K allele in the PA-Pet22b construct [39] and the
ANTXR1
R72,S136-EGFP construct. To isolate rat ANTXR2 (rANTXR2)
cDNA, rat liver and brain RNA were prepared by homogenizing
tissue from adult male Fischer 344 rats with TriZOL reagent
(Invitrogen, Carlsbad, California, United States) according to the
manufacturer’s instructions, followed by puriﬁcation with RNeasy
mini spin columns (Qiagen, Valencia, California, United States). The
rANTXR2 open reading frame was isolated using a nested, touch-
down PCR protocol on 3’ RACE cDNA products (Clontech, Palo Alto,
California, United States) with a Universal Primer Mix (Clontech) and
primer 5’ CCC GAG CCC AAG GGA CTG TGA GC 3’ for the ﬁrst
round, and primers 5’ ata gtc gac AC AGG ATG GTG GCC GGT CGG
TCC C and 5’ aa tag atc tgg TTG ATG TGG AAC TCG GGA GAA
GTT TAT GC in the second round PCR. Primers included engineered
SalI and BamHI restriction sites (underlined), respectively, for
cloning rANTXR2 as an EGFP fusion protein in the pLEGFP.N1
plasmid. The open reading frames of all constructs were conﬁrmed by
sequencing. The PA
D683N-Pet22b plasmid [34] was a gift from Jeremy
Mogridge.
PA receptor–deﬁcient CHO-R1.1 cells and CHO-R1.1 cells that
were engineered to stably express recombinant receptor-EGFP fusion
proteins, CMG2
489-EGFP or ATR/TEM8 sv2-EGFP, have been de-
scribed previously [22,34]. For transient expression of receptors,
approximately 5 3 10
6 CHO-R1.1 cells was transfected with 1 lgo f
receptor-EGFP fusion construct and 5 lg of pBSII KS(–) or pTRE2hyg
plasmids as carrier DNA and LipofectAMINE 2000 (Invitrogen)
according to the manufacturer’s instructions. Cells were split and
intoxicated at 24 h post-transfection, and analyzed for cell viability or
receptor cell surface expression at 48 h post-transfection.
PA and sANTXR2 protein production. The sANTXR2-mycHis
protein was puriﬁed from the extracellular supernatants of human
293 Freestyle cells (Invitrogen) stably expressing this protein as
described elsewhere [38]. The wild-type and altered forms of PA were
prepared from the periplasm of E. coli BL21 cells that had been
transformed with the PA-Pet22b, PA
D683N-Pet22b, or PA
D683K-Pet22b
plasmids, as described previously [40]. The PA proteins were puriﬁed
by FPLC with HiTrap QFF and Superose 12 (Amersham, Little
Chalfont, United Kingdom) or HiLoad Superdex 200 (Amersham)
columns, and the relative protein purity was determined by Image-
Quant analysis (Amersham) of Coomassie-stained protein samples
following SDS-PAGE.
Cell surface receptor expression analysis. Anti-ANTXR2 anti-
bodies were raised in chickens against the sANTXR2-mycHis
protein [22,38] that should include ANTXR2 residues 34 to 232 as
a mature protein (Aves Labs, Tigard, Oregon, United States).
Antibodies were afﬁnity puriﬁed against the same protein antigen
by FPLC with a HiTrap NHS-activated HP column (Amersham). For
ﬂow cytometric analysis of ANTXR2 expression on the surfaces of
transfected cells, cells were incubated with a 1:100 dilution of the
anti-ANTXR2 antibody, followed by a 1:1,000 dilution of an
AlexaFluor-633–conjugated goat anti-chicken antibody (Molecular
Probes, Eugene, Oregon, United States). All FACS data were
collected on an LSR ﬂow cytometer (BD Biosciences, San Diego,
California, United States) and analyzed with a FloJo software
package (Tree Star, Ashland, Oregon, United States). The geometric
mean of AlexaFluor-633 ﬂuorescence after incubation with primary
and secondary antibody was graphed after subtracting background
binding of cells incubated with secondary antibody. Cell surface
expression of human ANTXR1-EGFP, ANTXR2-EGFP,
ANTXR1
R72,S136-EGFP, and rat ANTXR2 proteins shown in Figure
4 was conﬁrmed by ﬂow cytometric analysis using an AlexaFluor-
633–conjugated monomeric form of PA83 (unpublished data).
PA binding and in vitro intoxication assays. PA binding to cells was
monitored by ﬂow cytometric analysis following incubations of cells
for 2 h on ice with 100 nM PA or PA
D683K, then with a 1:2,000 dilution
of an anti-PA rabbit polyclonal serum, and a 1:500 dilution of an
APC-conjugated anti-rabbit antibody (Molecular Probes) [22]. Intox-
ication was monitored by incubating samples of cells with LFN-DTA
[41] and either PA, PA
D683K,o rP A
D683N proteins. Cell viability was
measured 45 to 50 h later using the CellTiter-Glo reagent (Promega,
Madison, Wisconsin, United States). In the case of transiently
expressed receptors, samples of cells were incubated with LFN-DTA
and either PA, PA
D683K,o rP A
D683N proteins and analyzed by FACS 20
to 24 h later. Cell viability was determined by dividing the percentage
of live, EGFP-positive cells in the samples with complete toxin by that
in the LFN-DTA only control (100% cell viability). In all intoxications,
percent cell viability is the average from three samples, 6 SD.
Binding afﬁnity analysis. All experiments were performed at 25 8C
using the Biacore 2000 system and sensor chips with immobilized PA
proteins as described previously [35]. Concentrations of sANTXR2
proteins used ranged from 24 nM to 4.8 lM in HBS (10 mM HEPES
[pH 7.6], 150 mM NaCl) with either 1 mM CaCl2, 1 mM MgCl2,o r2
mM EDTA at pH 7.6. Serial injections were made at 10 ll/min,
followed by a 40-ll buffer injection to allow for off-rate measure-
ments. All kinetic data were analyzed using Origin Software. The
equilibrium dissociation constants were calculated from kinetic
measurements of the association and dissociation rate constants
according to KD ¼ koff/kon, and the errors were propagated. All results
described are the average values of two independent trials.
Rat intoxication challenge. Animal lethal toxin challenges were
performed according to protocols approved by the Scripps Institu-
tional Animal Care and Use Committee. Male Fischer 344 rats (180 to
200 g; Harlan) were anesthetized with isoﬂuoranes and inoculated
with 500 ll of a toxin mixture through a jugular vein cannula. The
toxin mixture was prepared for each group by mixing 8 lg of LF (List
Biological Laboratories, Campbell, California, United States) with 10
to 40 lg of puriﬁed PA or with 100 lgo fP A
D683K in a 500-ll volume
per rat. Rats recovered from anesthesia within 5 min and were
monitored for symptoms of intoxication and death (deﬁned by
cessation of respiration). The Student’s unpaired t-test (Prism) was
used for statistical analysis.
Supporting Information
Figure S1. Alignment of the Amino Acid Sequence from Human
ANTXR1 (hANTXR1), hANTXR2, and rANTXR2
Sequences were aligned by the ClustalW method (MacVector). The
actual hANTXR1 and hANTXR2 protein isoform sequences aligned
are indicated above. The dark line above the sequence indicates the I
domain region that binds PA. The residues of the MIDAS are
indicated with green boxes. The residues implicated in PA contact in
the hANTXR2-PA co-crystal structure are indicated with red boxes,
and the residues important for binding PA
D683N, as discussed in this
report, are indicated with purple boxes. Asterisks (*) and periods (.)
below the sequence designate conserved and similar residues,
respectively, at that site.
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Table S1. Oligonucleotide Primers for QuikChange Mutagenesis
(Stratagene)
Found at DOI: 10.1371/journal.ppat.0020111.st001 (43 KB DOC).
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank) accessions
numbers used in this paper are rat ANTXR1 I domain (DQ789143)
and cDNAs encoding the rANTXR2 open reading frame isolated
from rat liver and brain tissue RNAs (DQ486884 for each). The
Protein Data Bank (http://www.rcsb.org/pdb) accession number used
in this paper is UCSF Chimera (IT6B).
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